Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2020-11-03 Major Shareholding Noti…
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 2 TO THE SCHEDULE 13G
Major Shareholding Notification
2020-11-03 English
6-K
Regulatory Filings
2020-10-30 English
Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is used by Foreign Private Issuers to report material information that is made public outside of the U.S. The content is a press release announcing positive results from the interim analysis of the GENESIS Phase 3 Trial of Motixafortide, which is a material event. While the content is an Earnings Release (ER) or potentially an Interim Report (IR) in substance, the filing wrapper is Form 6-K. In the provided classification scheme, there is no specific code for Form 6-K. However, Form 6-K filings often contain material news that is not covered by the specific codes like ER, IR, or CAP. Given the nature of the announcement (clinical trial results leading to enrollment cessation) and the lack of a specific 6-K code, the most appropriate fallback category for a general, material regulatory announcement that doesn't fit the other specific categories (like 10-K, ER, IR) is 'Regulatory Filings' (RNS). The document length (8808 chars) is substantial, indicating it is the report/release itself, not just an announcement of a report (ruling out RPA).
2020-10-30 English
Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization
Report Publication Announcement Classification · 98% confidence The document is very short (2009 characters) and explicitly states: "Attached hereto is a report on*BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization* *FORM_6-K_10-30-2020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is often filed as an immediate report or used for material news). According to Rule 2 (The 'MENU VS MEAL' Rule), when a document announces that a report is attached or published, it should be classified as a Report Publication Announcement (RPA). The presence of the ISA and TASE headers confirms it is a regulatory filing, but RPA is more specific for this announcement format.
2020-10-30 English
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
Regulatory Filings Classification · 97% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is a report of a foreign private issuer required under the Securities Exchange Act of 1934. This form is generally used to report material information that the company is required to disclose to its home country's regulators or stock exchange, or that it makes public in its home country. While the content is an 'Earnings Release' (announcing a clinical trial initiation), the regulatory filing wrapper is a Form 6-K. Since Form 6-K is a periodic/current report for foreign issuers, it often serves a similar function to 10-Q or 8-K filings in the US context, but it does not map directly to the provided US-centric codes (10-K, MRQ, ER). Given the options, the most appropriate classification for a general, non-standardized regulatory filing that contains material information but doesn't fit the specific financial report types (10-K, IR, ER) is the general regulatory fallback category. However, the content is a press release announcing clinical trial progress, which is material information. If we must choose from the provided list, and recognizing that Form 6-K is a mandatory regulatory filing, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the best fit for the *form type* itself, as it is not a full Annual Report (10-K), Interim Report (IR), or a pure Earnings Release (ER) which usually only contains summarized financials. Since the document is substantial (over 12,000 characters) and is the filing itself, not an announcement of a filing, RPA is incorrect. RNS is the most suitable fallback for a non-US specific SEC filing form.
2020-10-29 English
BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer
Report Publication Announcement Classification · 98% confidence The document is very short (1935 characters) and explicitly states, "Attached hereto is a report on*BioLineRx Announces Initiation of Phase 2 Clinical Trial in First-Line Metastatic Pancreatic Cancer* *FORM_6-K_30-Sep-2020_isa.pdf*". This structure—a brief announcement referencing an attached or linked primary document (in this case, a Form 6-K, which is a general SEC filing for foreign private issuers)—fits the definition of a Report Publication Announcement (RPA). It is announcing the publication of a report rather than being the report itself. Since RPA is a specific category for such announcements, it is preferred over the general fallback RNS.
2020-10-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.